Stephenson Cancer Center, OU Health
Oklahoma's only NCI-designated centre, consistently among the top enrollers in NRG gynaecologic trials and home of the SOLO1 and MIRASOL ovarian cancer lead investigator.
NCI-designated in 2018, Stephenson Cancer Center is the only NCI centre in Oklahoma and serves a state with large American Indian populations. Its gynaecologic oncology group is one of the most productive in the NCI's National Clinical Trials Network: Kathleen Moore led SOLO1, which established olaparib maintenance in newly diagnosed BRCA-mutated ovarian cancer, and MIRASOL, which confirmed the folate receptor alpha ADC mirvetuximab soravtansine in platinum-resistant disease. The Oklahoma Tobacco Research Center and TSET-funded cancer control programmes address the state's high smoking rates, and the centre runs an active phase 1 programme.
- Gynaecologic oncology trials (NRG)
- Ovarian cancer (PARP inhibitors, FRα ADCs)
- Tobacco research
Pages like this
not linked directly; found by shared links- PersonUrsula A. Matulonis
Shares Mirvetuximab soravtansine, Folate receptor alpha, Olaparib, PARP.
- TrialMIRASOL / GOG-3045
Shares Mirvetuximab soravtansine, Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).
- TrialSOLO-1
Shares PARP inhibitors, Olaparib, PARP, Ovarian cancer.
- TrialRAINFOL-01 (Rina-S)
Shares Folate receptor alpha, Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- PersonAlan Ashworth
Shares PARP inhibitors, Olaparib, PARP, Ovarian cancer.
- PersonAmit M. Oza
Shares Olaparib, PARP, Endometrial cancer, Ovarian cancer.
- ProductLuveltamab tazevibulin
Shares Folate receptor alpha, Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- IdeaA functional test for homologous recombination deficiency validated across laboratories
Shares PARP inhibitors, Olaparib, PARP, Ovarian cancer.